{
  "success": true,
  "pagesUsed": [
    0,
    1,
    2,
    3,
    4,
    5,
    6,
    7,
    15,
    17,
    18,
    19,
    20,
    23,
    24,
    25,
    26,
    27,
    30,
    31
  ],
  "modelUsed": "gemini-3-flash-preview",
  "confidence": 1.0,
  "documentStructure": {
    "documentContentReferences": [
      {
        "id": "ref_1",
        "name": "PD-L1 Population Definition",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "7.5.1",
        "sectionTitle": "Archived Tumor Biospecimens and De Novo Tumor Biopsies",
        "description": "Reference for the prospectively defined patient population for primary endpoints."
      },
      {
        "id": "ref_2",
        "name": "Treatment Continuation Details",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "5.4.4",
        "sectionTitle": "Treatment After Initial Evidence of Radiologic Disease Progression in Both Arms",
        "description": "Details on treatment continuation after initial evidence of disease progression."
      },
      {
        "id": "ref_3",
        "name": "Study Withdrawal Reference",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "6.5",
        "sectionTitle": "Patient Withdrawal",
        "description": "Reference for criteria regarding study withdrawal."
      },
      {
        "id": "ref_4",
        "name": "Dose Modification Guidelines",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "5.4.6",
        "sectionTitle": "Recommended Dose Modifications",
        "description": "Reference for adjusting treatment due to drug-related toxicities."
      },
      {
        "id": "ref_5",
        "name": "Testing Strategy Figure",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "9.1",
        "sectionTitle": "Sample Size Determination",
        "description": "Reference to Figure 2 regarding the gatekeeping procedure for testing populations."
      },
      {
        "id": "ref_6",
        "name": "Group Sequential Design",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "9.6",
        "sectionTitle": "Interim Analysis",
        "description": "Reference for significance levels taking into account the group sequential nature of the design."
      },
      {
        "id": "ref_7",
        "name": "CTCAE Appendix",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "Appendix 6",
        "sectionTitle": "National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE)",
        "description": "Reference for grading adverse events and laboratory abnormalities."
      }
    ],
    "commentAnnotations": [
      {
        "id": "annot_1",
        "text": "Visit Identifiers: All assessments should be performed prior to dosing with study treatments unless otherwise indicated.",
        "annotationType": "Footnote",
        "instanceType": "CommentAnnotation",
        "sourceSection": "Schedule of Activities",
        "pageNumber": 43
      },
      {
        "id": "annot_2",
        "text": "Home Blood Pressure Monitoring: Patients should be instructed to contact the site immediately if systolic BP > 150 mm Hg or diastolic BP > 100 mm Hg.",
        "annotationType": "Note",
        "instanceType": "CommentAnnotation",
        "sourceSection": "Schedule of Activities - Footnote 8",
        "pageNumber": 44
      },
      {
        "id": "annot_3",
        "text": "irRECIST-defined antitumor activity will no longer be collected as per PACL dated 02 September 2019.",
        "annotationType": "Clarification",
        "instanceType": "CommentAnnotation",
        "sourceSection": "Schedule of Activities - Footnote 16",
        "pageNumber": 45
      },
      {
        "id": "annot_4",
        "text": "Cytology samples (eg, FFPE cell pellet from Fine Needle Aspiration biopsy) are not acceptable.",
        "annotationType": "Footnote",
        "instanceType": "CommentAnnotation",
        "sourceSection": "Schedule of Activities - Footnote 26",
        "pageNumber": 47
      }
    ],
    "studyDefinitionDocumentVersions": [
      {
        "id": "ver_1",
        "versionNumber": "8",
        "status": "Final",
        "instanceType": "StudyDefinitionDocumentVersion",
        "versionDate": "2020-01-03",
        "description": "Final Protocol Amendment 8",
        "amendmentNumber": "Amendment 8"
      }
    ],
    "summary": {
      "referenceCount": 7,
      "annotationCount": 4,
      "versionCount": 1
    }
  }
}